Abstract Details

Title Association of serum glucose/potassium ratio with the prognosis of aneurysmal subarachnoid hemorrhage: a systematic review with meta-analysis

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S36 - Cerebrovascular Disease and Interventional Neurology: Basic and Translational Science (1:36 PM-1:48 PM)

Poster/Presentation
Number 004

Objective To conduct a systematic review with meta-analysis to evaluate the current evidence on the prognostic value of GPR in patients with aSAH.

Background Currently, the glucose/potassium ratio (GPR) is an important biomarker indicating the abundant release of catecholamines during aneurysmal subarachnoid hemorrhage (aSAH), which triggers different alterations in patients.

Design/Methods A systematic search was conducted in PubMed, Embase, Scopus, Web of Science, Google Scholar, Lilacs, and Cochrane Library until April 2022. The quality of the included studies was assessed using the New Castle-Ottawa tool. A meta-analysis with randomized effects model was applied using the Paule-Mendel estimator to estimate the pooled effect of the outcome and a narrative synthesis when this was not possible. GRADE criteria for continuous outcomes and narrative review were used to assess the certainty of the evidence.

Results Four of 368 studies were selected. With high certainty, we reported that a significant increase in GPR values was found in patients with a poor outcome according to Glasgow Scale Score (MD: 14.81; 95 CI: 12.47;17.15; I2=0%). With moderate certainty, we found a specificity of 0.50 for mortality at 3 months and with high certainty, a sensitivity of 0.90 for the mortality at 3 months. With a moderate certainty, one study showed a mean difference of 5.3 between poor and good prognosis (Rankin Scale > 2 at 3 months) and with the same certainty, we found a specificity of 0.63 for poor prognosis at 1 year (Rankin Scale > 2).

Conclusions

With moderate certainty of the evidence, we found that GPR is useful as a prognostic biomarker in patients with aSAH. However, more research is required to control possible confounding variables through sensitivity and specificity analysis.

Authors/Disclosures
Claudia Cruzalegui Bazán PRESENTER	Miss Cruzalegui Bazán has nothing to disclose.
Milenka Del Rosario D. Cierto Torre (None)	Miss Cierto Torre has nothing to disclose.
Renzo G. Vallejos	Mr. Vallejos has nothing to disclose.
Anaiz D. Ticona Flores	Miss Ticona Flores has nothing to disclose.
	No disclosure on file
Miguel F. Cabanillas Lazo	Mr. Cabanillas Lazo has nothing to disclose.

��ɫ��

��ɫ��